Immunology Investor Event slide image

Immunology Investor Event

sanofi Next-generation of oral pathway medicines soluble TNFα TNFα Inh YYY IL-17A Y IL-17A Blocker IL1/IL18/IL33/IL36 Y Y Y Y Antibody-like efficacy with oral convenience Soluble TNFα Inhibitor (SAR441566) selectively blocks TNFR1 signaling Oral IL-17A Blocker target a key pro-inflammatory pathway TNFR1 INF-R TLR4 IL-17R BCR FcR TLRS IL-XR RIPK1 RIPK1 Inh BTK Inh BTK IRAK4 IRAK4 Inh Tissue Inflammation Dermatology | Respiratory | Gastroenterology | Rheumatology 48 Immunology Investor Event Tackling nodal targets RIPK1 Inhibitor (eclitasertib) targets a master regulator of cell death and proinflammatory cytokine production BTK Inhibitor covalent reversible (rilzabrutinib) targets 2 key molecular pathways IRAK4 Degrader - blockade of kinase and scaffold function for maximal disease impact
View entire presentation